225Ac-FPI-2265 (225Ac-PSMA-I&T) is another alpha emitter analogue of the marketed 177Lu-Vipivotide tetraxetan (PSMA-617) and the 225Ac-labeled analogue of 177Lu-PSMA-I&T for the treatment of metastasized castration resistant prostate cancer (mCRPC) patients. The running TATCIST trial is designed to evaluate patients with mCRPC with progressive disease, including patients who are naïve to PSMA targeted radiopharmaceuticals and those who have been pre-treated with 177Lu-based PSMA radiopharmaceuticals.

Target/Mechanism: PSMA

Carrier/Ligand: PSMA-I&T

Radiation Type: alpha particle (α)